208 related articles for article (PubMed ID: 26851399)
21. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
[TBL] [Abstract][Full Text] [Related]
23. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
Fiore M; Palassini E; Fumagalli E; Pilotti S; Tamborini E; Stacchiotti S; Pennacchioli E; Casali PG; Gronchi A
Eur J Surg Oncol; 2009 Jul; 35(7):739-45. PubMed ID: 19110398
[TBL] [Abstract][Full Text] [Related]
24. Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.
Mohammadi M; IJzerman NS; Hollander DD; Bleckman RF; Oosten AW; Desar IME; Reyners AKL; Steeghs N; Gelderblom H
Target Oncol; 2023 May; 18(3):415-423. PubMed ID: 37079223
[TBL] [Abstract][Full Text] [Related]
25. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
Zuidema S; Desar IME; van Erp NP; Kievit W
Br J Clin Pharmacol; 2019 Sep; 85(9):1994-2001. PubMed ID: 31112617
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
Den Hollander D; Van der Graaf WTA; Desar IME; Le Cesne A
Acta Oncol; 2019 Nov; 58(11):1648-1654. PubMed ID: 31345082
[No Abstract] [Full Text] [Related]
27. Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure.
Bins S; Eechoute K; Kloth JS; de Man FM; Oosten AW; de Bruijn P; Sleijfer S; Mathijssen RH
Clin Pharmacokinet; 2017 Mar; 56(3):305-310. PubMed ID: 27461250
[TBL] [Abstract][Full Text] [Related]
28. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
Steinert DM; Oyarzo M; Wang X; Choi H; Thall PF; Medeiros LJ; Raymond AK; Benjamin RS; Zhang W; Trent JC
Cancer; 2006 Apr; 106(7):1617-23. PubMed ID: 16518826
[TBL] [Abstract][Full Text] [Related]
29. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
[TBL] [Abstract][Full Text] [Related]
30. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
Lee CK; Goldstein D; Gibbs E; Joensuu H; Zalcberg J; Verweij J; Casali PG; Maki RG; Cioffi A; Mcarthur G; Lord SJ; Yip D; Kanjanapan Y; Rutkowski P
Eur J Cancer; 2015 May; 51(7):852-60. PubMed ID: 25801699
[TBL] [Abstract][Full Text] [Related]
32. Ten-year review of gastrointestinal stromal tumours at a tertiary referral hospital in New Zealand.
Siu J; Lim M; Fischer J; Dobbs B; Wakeman C; Ing A; Frizelle F
ANZ J Surg; 2016 Mar; 86(3):162-6. PubMed ID: 24325620
[TBL] [Abstract][Full Text] [Related]
33. Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
Durosinmi MA; Salawu L; Lawal OO; Ojo OS; Alatishe OI; Oyekunle AA; Bolarinwa RA; Adisa AO; Badmos K; Anomneze EE; Ayansanwo AO
Afr J Med Med Sci; 2013 Dec; 42(4):325-32. PubMed ID: 24839736
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
Angelini S; Pantaleo MA; Ravegnini G; Zenesini C; Cavrini G; Nannini M; Fumagalli E; Palassini E; Saponara M; Di Battista M; Casali PG; Hrelia P; Cantelli-Forti G; Biasco G
Pharmacol Res; 2013 Feb; 68(1):1-6. PubMed ID: 23127916
[TBL] [Abstract][Full Text] [Related]
35. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
Yoo C; Ryu MH; Nam BH; Ryoo BY; Demetri GD; Kang YK
Eur J Cancer; 2016 Jan; 52():201-8. PubMed ID: 26699729
[TBL] [Abstract][Full Text] [Related]
36. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
[TBL] [Abstract][Full Text] [Related]
37. Surgical Treatment of Gastrointestinal Stromal Tumors Located in the Stomach in the Imatinib Era.
Stiekema J; Kol S; Cats A; Yazdi AT; van Coevorden F; van Sandick JW
Am J Clin Oncol; 2015 Oct; 38(5):502-7. PubMed ID: 24064754
[TBL] [Abstract][Full Text] [Related]
38. The role of imatinib plasma level testing in gastrointestinal stromal tumor.
George S; Trent JC
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S45-50. PubMed ID: 21140148
[TBL] [Abstract][Full Text] [Related]
39. [Gastrointestinal stromal tumour: our experience].
Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
[TBL] [Abstract][Full Text] [Related]
40. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
